Alzamend Neuro, Inc.
ALZN
$0.67
-$0.04-5.63%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 62.97% | 51.30% | 72.38% | 74.24% | 50.93% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 139.62% | 139.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -56.43% | -74.46% | -75.47% | -83.31% | -87.63% |
| Change in Net Operating Assets | -223.27% | -295.82% | -21.05% | -216.77% | -79.51% |
| Cash from Operations | 29.93% | -124.67% | 67.99% | 36.17% | -12.43% |
| Capital Expenditure | -- | -- | 38.86% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 38.86% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -28.60% | 6,387.29% | -- | 134,850.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -67.43% | 34,702.21% | -- | 759,850.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -987.56% | 293.88% | 123.74% | 104.17% | 104.58% |